MedTrace Logo

Use of Beta-blockers and Risk of New Onset Diabetes

NCT01587638 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12336

Last updated 2012-04-30

No results posted yet for this study

Summary

This study used an observational, retrospective cohort design to compare the presence and timing of new-onset diabetes (NOD) between hypertensive patients initiating therapy with carvedilol immediate-release (IR) and carvedilol controlled-release (CR) vs the following cardioselective beta blockers (BBs): atenolol, metoprolol succinate, and metoprolol tartrate (referred to hereafter as 'other BB').

The aim of the study was to investigate the likelihood of developing NOD among hypertensive patients initiating carvedilol therapy vs other BB therapy in a real world setting derived from data contained in a large United States (US) managed care database.

Conditions

Interventions

DRUG

carvedilol

carvedilol immediate-release (IR) and carvedilol controlled-release (CR)

DRUG

cardio selective betablocker

atenolol, metoprolol succinate, and metoprolol tartrate

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01587638 on ClinicalTrials.gov